Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
Date:6/5/2008

NEW YORK, June 5 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). The full 56-page report can be found at http://www.crystalra.com .

Arana Therapeutics Ltd. ("Arana" or "the Company") is a biotechnology company developing next-generation antibody therapeutics to treat inflammatory diseases and cancer. Arana's business is divided into two sectors: (1) protein engineering technologies; and (2) therapeutics development. The Company's technology platform includes its Superhumanisation(TM), Synhumanisation(R), and EvoGene(TM) proprietary processes. Application of these technologies can transform lead proteins, including antibodies, into safe, potent therapeutic candidates. The resulting products may be less immunogenic (less likely to cause side effects) yet retain the crucial binding properties of the starting antibody.

At present, the Company licenses its protein engineering platform to CSL Ltd. (CSL-ASX), GlaxoSmithKline plc (GSK-NYSE), Aveo Pharmaceuticals, Inc., and Vegenics Ltd. Additionally, Arana can use its technologies to decrease the timeline and minimize the financial risks of its therapeutic antibody development. The Company does this by further enhancing already validated targets that would otherwise be excluded from development due to existing competitor patents.

Arana's product pipeline consists of eight candidates targeting inflammatory diseases as well as bone, lung, and colorectal cancer, melanoma, leukemia, and solid tumors. ART621, the Company's most advanced candidate, is a Tumor Necrosis Factor alpha (TNF alpha)-blocker for rheumatoid arthritis (RA), psoriasis, and Crohn's disease. In March 2008, the Company commenced Phase II clinical trials of ART621 in psoriasis patients. Within Arana's Cancer Franchise, the lead product candidate is ART010, an engineered version of a naturally occurring protein being developed for treating cancer related to bone disease and osteoporosis. Arana expects to begin manufacturing ART010 in 2008 and could enter Phase I trials in late 2009. Arana has headquarters in Sydney, Australia, with facilities in Melbourne, Australia, and San Francisco, California.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
2. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
3. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. Researchers outline structure of largest nonvirus particle ever crystallized
6. 3-D photonic crystals will revolutionize telecommunications
7. Recombinant Human Renin - Crystallographic Grade
8. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
9. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):